Alkermes (ALKS) Competitors $35.33 -0.17 (-0.49%) Closing price 03:59 PM EasternExtended Trading$35.44 +0.11 (+0.31%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALKS vs. BIIB, UTHR, INCY, BMRN, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Alkermes vs. Biogen United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alkermes (NASDAQ:ALKS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Which has more volatility & risk, ALKS or BIIB? Alkermes has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Is ALKS or BIIB more profitable? Alkermes has a net margin of 23.57% compared to Biogen's net margin of 16.87%. Alkermes' return on equity of 30.80% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.57% 30.80% 19.09% Biogen 16.87%14.98%8.76% Does the media refer more to ALKS or BIIB? In the previous week, Biogen had 35 more articles in the media than Alkermes. MarketBeat recorded 55 mentions for Biogen and 20 mentions for Alkermes. Biogen's average media sentiment score of 0.57 beat Alkermes' score of 0.48 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 19 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable earnings & valuation, ALKS or BIIB? Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.68$367.07M$2.1716.23Biogen$9.68B2.12$1.63B$11.1912.53 Does the MarketBeat Community prefer ALKS or BIIB? Biogen received 1115 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 71.55% of users gave Biogen an outperform vote while only 70.52% of users gave Alkermes an outperform vote. CompanyUnderperformOutperformAlkermesOutperform Votes70170.52% Underperform Votes29329.48% BiogenOutperform Votes181671.55% Underperform Votes72228.45% Do insiders & institutionals believe in ALKS or BIIB? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 4.9% of Alkermes shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ALKS or BIIB? Alkermes presently has a consensus price target of $38.36, suggesting a potential upside of 8.96%. Biogen has a consensus price target of $211.85, suggesting a potential upside of 51.16%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82Biogen 0 Sell rating(s) 17 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummaryAlkermes and Biogen tied by winning 9 of the 18 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.73B$7.09B$5.82B$9.06BDividend YieldN/A2.87%4.78%3.85%P/E Ratio16.246.0726.1619.03Price / Sales3.68320.22455.9477.31Price / Cash13.5267.8344.0437.47Price / Book3.916.827.704.73Net Income$367.07M$138.11M$3.18B$245.69M7 Day Performance-1.89%-1.02%-1.02%-1.33%1 Month Performance16.98%-0.54%1.10%-1.00%1 Year Performance20.66%-2.43%18.06%15.52% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes3.6702 of 5 stars$35.33-0.5%$38.36+8.6%+16.8%$5.74B$1.56B16.281,800BIIBBiogen4.7483 of 5 stars$137.33-0.8%$211.96+54.3%-37.5%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.3629 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5343 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9187 of 5 stars$64.85+0.7%$94.20+45.3%-22.5%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBIXNeurocrine Biosciences4.9717 of 5 stars$115.02-1.6%$166.90+45.1%-12.5%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionGap UpEXELExelixis4.6309 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeEXASExact Sciences4.6345 of 5 stars$49.31-2.5%$72.76+47.6%-21.1%$9.13B$2.50B-42.146,600Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRGENRepligen4.2789 of 5 stars$146.92+0.5%$182.91+24.5%-18.6%$8.23B$638.76M-397.071,783Earnings ReportAnalyst ForecastNews CoverageHALOHalozyme Therapeutics4.4455 of 5 stars$58.29-0.5%$60.89+4.5%+59.6%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.3133 of 5 stars$337.20-4.1%$351.67+4.3%+52.8%$7.35BN/A-13.4490 Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Exact Sciences Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALKS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
